Crispr Therapeutics (CRSP) reported encouraging updated Phase I data for its in vivo liver editing candidate CTX310, showing up to 82% reduction in triglycerides and 86% in LDL cholesterol, with safety in line with earlier findings, Chardan analyst Geulah Livshits tells investors in a research note. The company delayed guidance for its next program, CTX320 targeting Lp(a), to the first half of 2026, while full CTX310 data is expected in the second half of 2025. Despite questions around market demand for one-time gene editing in cardiovascular disease, Eli Lilly’s (LLY) $1B+ deal for Verve (VERV) supports investor confidence in the space, potentially boosting Crispr’s valuation, the firm says. Chardan has a Buy rating and $82 price target on Crispr Therapeutics shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Buy Rating Affirmed for Crispr Therapeutics AG Due to Promising Clinical Data and Competitive Positioning
- Strategic Alignment and Positive Clinical Data Reinforce Buy Rating for Crispr Therapeutics AG
- CRISPR Therapeutics Updates on Cardiovascular Programs
- Crispr announces updates across in vivo cardiovascular disease progams
- CRISPR Therapeutics AG Shareholders Approve Key Proposals